medi-528
mAbexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2004 (NCT00192296)
Timeline
Indications
Studied for
Mechanism of action
- Interleukin-9INHIBITOR
IL9 inhibitor
Humanized immunoglobulin (Ig) G1 mAb that neutralizes the activity of human IL-9.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1743012 ↗
Also known as
- 7f3com-2h2
- enokizumab
- medi528
- medi-528
- medi-528
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00968669 | Phase 2 | Dec 1, 2009 | MedImmune |
| NCT00590720 | Phase 2 | Mar 1, 2008 | MedImmune |
| NCT00483041 | Phase 2 | Jul 1, 2007 | MedImmune |
| NCT00507130 | Phase 2 | Jul 1, 2007 | MedImmune |
| NCT00394654 | Phase 2 | Nov 1, 2006 | MedImmune |
| NCT00116168 | Phase 1 | Jun 1, 2005 | MedImmune |
| NCT00192296 | Phase 1 | Aug 1, 2004 | MedImmune |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 7 | 7 | 2 | 2004 |
1 organizations
Page 1 / 1